Biotechnology company Alligator Bioscience (STO:ATORX) said on Thursday that it has decided to focus its resources on two proprietary candidate drugs, ATOR-1017 and mitazalimab.
Positive safety and strong Proof of Mechanism data support moving both of these potential new cancer treatments into clinical efficacy (Phase Ib/II) studies in 2021, the company said.
According to Alligator Bioscience CEO Per Norlén, ATOR-1017 and mitazalimab both have potential in "large cancer indications with high medical need and billion-dollar markets".
Alligator will complete the ongoing dose-escalation study with the bispecific ATOR-1015 as planned during the fourth quarter of 2020, after which it will be partnered for further development.
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder
WuXi AppTec's Nantong site receives 2025 Architizer A+Award
MGI partners with Negedia to enhance genomic sequencing in Italy
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress